Compare with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs JUBILANT LIFE SCIENCES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES JUBILANT LIFE SCIENCES ALKEM LABORATORIES/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 25.0 15.8 158.8% View Chart
P/BV x 6.0 2.9 205.1% View Chart
Dividend Yield % 0.8 0.5 158.7%  

Financials

 ALKEM LABORATORIES   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-20
JUBILANT LIFE SCIENCES
Mar-19
ALKEM LABORATORIES/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs2,720898 302.9%   
Low Rs1,660618 268.9%   
Sales per share (Unadj.) Rs697.9572.0 122.0%  
Earnings per share (Unadj.) Rs96.136.2 265.3%  
Cash flow per share (Unadj.) Rs117.359.5 197.0%  
Dividends per share (Unadj.) Rs25.004.50 555.6%  
Dividend yield (eoy) %1.10.6 192.2%  
Book value per share (Unadj.) Rs515.2301.9 170.7%  
Shares outstanding (eoy) m119.57159.28 75.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.11.3 236.9%   
Avg P/E ratio x22.820.9 108.9%  
P/CF ratio (eoy) x18.712.7 146.7%  
Price / Book Value ratio x4.32.5 169.4%  
Dividend payout %26.012.4 209.4%   
Avg Mkt Cap Rs m261,879120,694 217.0%   
No. of employees `00014.32.4 599.6%   
Total wages/salary Rs m15,05519,260 78.2%   
Avg. sales/employee Rs Th5,822.638,120.6 15.3%   
Avg. wages/employee Rs Th1,050.58,058.4 13.0%   
Avg. net profit/employee Rs Th802.02,414.3 33.2%   
INCOME DATA
Net Sales Rs m83,44491,108 91.6%  
Other income Rs m1,042357 291.6%   
Total revenues Rs m84,48691,466 92.4%   
Gross profit Rs m14,73417,390 84.7%  
Depreciation Rs m2,5283,709 68.1%   
Interest Rs m6512,198 29.6%   
Profit before tax Rs m12,59811,840 106.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,802 0.0%   
Tax Rs m1,1053,268 33.8%   
Profit after tax Rs m11,4935,770 199.2%  
Gross profit margin %17.719.1 92.5%  
Effective tax rate %8.827.6 31.8%   
Net profit margin %13.86.3 217.5%  
BALANCE SHEET DATA
Current assets Rs m54,96045,848 119.9%   
Current liabilities Rs m32,43320,897 155.2%   
Net working cap to sales %27.027.4 98.6%  
Current ratio x1.72.2 77.2%  
Inventory Days Days8057 140.1%  
Debtors Days Days7251 141.6%  
Net fixed assets Rs m32,71065,498 49.9%   
Share capital Rs m239159 150.1%   
"Free" reserves Rs m61,36847,930 128.0%   
Net worth Rs m61,60748,089 128.1%   
Long term debt Rs m1,59242,429 3.8%   
Total assets Rs m99,433114,685 86.7%  
Interest coverage x20.46.4 318.8%   
Debt to equity ratio x00.9 2.9%  
Sales to assets ratio x0.80.8 105.6%   
Return on assets %12.26.9 175.8%  
Return on equity %18.712.0 155.5%  
Return on capital %21.012.4 168.9%  
Exports to sales %19.10-   
Imports to sales %3.00-   
Exports (fob) Rs m15,917NA-   
Imports (cif) Rs m2,483NA-   
Fx inflow Rs m16,06112,422 129.3%   
Fx outflow Rs m2,48317,227 14.4%   
Net fx Rs m13,578-4,805 -282.6%   
CASH FLOW
From Operations Rs m5,85111,215 52.2%  
From Investments Rs m-7,414-10,118 73.3%  
From Financial Activity Rs m7926,574 12.0%  
Net Cashflow Rs m-7317,612 -9.6%  

Share Holding

Indian Promoters % 66.9 45.6 146.7%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 33.1 8.7 380.5%  
FIIs % 0.0 21.2 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 21.1 -  
Shareholders   68,381 23,815 287.1%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   IPCA LABS  NOVARTIS  FRESENIUS KABI ONCO.  PROCTER & GAMBLE HEALTH  GSK PHARMA  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 531 Points; Reliance Industries & IndusInd Bank Fall 5%(Closing)

Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY20); Net Profit Up 358.8% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 358.8% YoY). Sales on the other hand came in at Rs 24 bn (up 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY20); Net Profit Down 24.0% (Quarterly Result Update)

Feb 1, 2020 | Updated on Feb 1, 2020

For the quarter ended December 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 24.0% YoY). Sales on the other hand came in at Rs 23 bn (down 2.6% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY20); Net Profit Up 18.9% (Quarterly Result Update)

Oct 31, 2019 | Updated on Oct 31, 2019

For the quarter ended September 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 18.9% YoY). Sales on the other hand came in at Rs 23 bn (down 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

One Chart to See Before You Sell(Fast Profits Daily)

Jan 22, 2021

In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.

Invest in the Multibaggers of 2021 and Beyond(Profit Hunter)

Jan 21, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Jan 25, 2021 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS